The current T3N0M0 stage includes a variety of locally advanced tumor features that
may be associated with disparate outcomes after surgery and should be re-examined
in the era of immunotherapy.
Abbreviations:
CWI (Chest wall invasion), IASLC (International Association for the Study of Lung Cancer), NSCLC (Non-small cell lung cancer)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Seminars in Thoracic and Cardiovascular SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.J Thorac Oncol. 2016; 11 (PMID: 26762738): 39-51https://doi.org/10.1016/j.jtho.2015.09.009
- Oncologic outcomes of patients with resected T3N0M0 non-small cell lung cancer.Semin Thorac Cardiovasc Surg. 2022; (S1043-0679(22)00206-4Epub ahead of print. PMID: 36038080)https://doi.org/10.1053/j.semtcvs.2022.08.007
- CheckMate 816 Investigators. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.N Engl J Med. 2022; 386 (Epub 2022 Apr 11. PMID: 35403841): 1973-1985https://doi.org/10.1056/NEJMoa2202170
- IMpower010 Investigators. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomized, multicenter, open-label, phase 3 trial.Lancet. 2021; 398 (Epub 2021 Sep 20. Erratum in: Lancet. 2021 Sep 23: PMID: 34555333): 1344-1357https://doi.org/10.1016/S0140-6736(21)02098-5
Article info
Publication history
Published online: September 20, 2022
Publication stage
In Press Journal Pre-ProofFootnotes
Disclosures: The authors have no conflicts of interest to disclose.
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Oncologic Outcomes of Patients With Resected T3N0M0 Non-small Cell Lung CancerSeminars in Thoracic and Cardiovascular Surgery
- PreviewIn the eighth edition TNM staging, the T3N0M0 category represents a heterogeneous group of non-small cell lung cancers (NSCLC). This study aims to compare the oncologic outcomes associated with individual T3 features. We performed a single-institution, retrospective analysis of 280 consecutive patients with pT3N0M0 NSCLC. Multivariate regression models were used to estimate associations of clinical factors with oncologic outcomes. The patients were grouped according to their T3 features into 4 prognostic groups: chest wall infiltration (CWI-PG), largest diameter >5 cm and ≤7 cm (Size-PG), presence of a satellite nodule (SN-PG), and all other T3 features.
- Full-Text
- Preview
